Taro Pharmaceutical Industries Ltd (NYSE:TARO)
| 37.72 Delayed Data As of Sep 27 |  -0.08 / -0.21%Today’s Change | 22.89 Today|||52-Week Range 42.22 | +29.89% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $1.4B |
Company Description
Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada and Israel. Its products include semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules and tablets, in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The company was founded in 1950 and is headquartered in Haifa Bay, Israel.
Contact Information
Taro Pharmaceutical Industries Ltd. 14 Hakitor Street Haifa Bay Haifa 2624761 |
Employees
Shareholders
| Other institutional | 7.42% |
| Mutual fund holders | 6.02% |
| Individual stakeholders | 12.06% |
Top Executives
| Uday Vijaykumar Baldota | Chief Executive Officer & Director |
| William J. Coote | Chief Financial & Accounting Officer |
| Hagai Reingold | Vice President & Head-Operations |
| Avi Avramoff | Vice President & Head-Research & Development |
| Richard Glaze | Vice President & Head-Information Technology |
